Thermo Fisher Scientific Inc. $TMO is Mccarter Private Wealth Services LLC’s 9th Largest Position

Mccarter Private Wealth Services LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,533 shares of the medical research company’s stock after selling 170 shares during the period. Thermo Fisher Scientific comprises about 2.8% of Mccarter Private Wealth Services LLC’s investment portfolio, making the stock its 9th biggest holding. Mccarter Private Wealth Services LLC’s holdings in Thermo Fisher Scientific were worth $4,246,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth $35,000. Finally, Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $37,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on TMO shares. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Argus cut their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday. They issued an “outperform” rating on the stock. Finally, UBS Group boosted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 295 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total value of $147,511.80. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock worth $8,593,838 over the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $483.4280 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $182.55 billion, a P/E ratio of 27.96, a P/E/G ratio of 2.64 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The business’s 50-day moving average is $441.06 and its 200 day moving average is $458.02.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.